Cerner and Omnicell Ratings Maintained Following Healthcare Conference

Cerner Corporation's CERN well-attended user conference highlighted the need for change in healthcare, Piper Jaffray reports. Healthcare reform and accountable care organizations (ACOs) garnered much attention among attendees, who reportedly agree that the formation of ACOs are inevitable to be competitive and will dramatically change the rules of reimbursement. “Well prepared hospitals implementations are thinking beyond Meaningful Use and investing in medication cabinets to close the medication loop, which bodes well for Cerner and Omnicell, Inc. OMCL,” Piper Jaffray writes, announcing that it maintains its Overweight rating for both companies. Cerner currently trades for $85.53; Omnicell trades for $12.99.